The trial will analyse XMT-1660 for treating individuals with solid tumours, including endometrial and ovarian cancers. Credit: KGH / commons.wikimedia.org.

Mersana Therapeutics has commenced the dosing of subjects in the Phase I clinical trial of XMT-1660 to treat individuals with solid tumours, including breast, endometrial, and ovarian cancers. 

The multicentre trial will assess XMT-1660’s safety, tolerability, and anti-tumour activity in such solid tumour patients. 

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The preliminary dose escalation part of the trial will analyse the safety and tolerability of XMT-1660 as a monotherapy. 

In the dose expansion segment of the trial, the tolerability and efficacy of XMT-1660 will be evaluated. 

Investigator-evaluated objective response rate and duration of response are the primary endpoints of this portion of the trial.

XMT-1660 is a Dolasynthen antibody-drug conjugate (ADC) that acts on B7-H4.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

It has a target-streamlined drug-to-antibody ratio and the company’s DolaLock microtubule inhibitor payload established clinically, with a controlled bystander effect. 

B7-H4 is overexpressed in various cancers, including breast, endometrial, and ovarian tumours. 

The therapy also showed strong anti-tumour activity in various models representing each of these cancer types and in multiple patient-obtained xenograft models in pre-clinical studies.

Mersana Therapeutics president and CEO Anna Protopapas said: “The initiation of this Phase I trial represents an important milestone for Mersana as we continue to build our pipeline across three ADC platforms and seek to further demonstrate the potential of our Dolalock payload and Dolasynthen platform. 

“Based on our promising preclinical data, we believe XMT-1660 has the potential to serve as a highly impactful cancer treatment.”

The clinical-stage biopharma firm discovers and develops ADCs that act on cancers in areas of increased unmet medical need.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact